Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Neumora Therapeutics, Inc. (NMRA) had Return on Equity of -228.10% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-236.93M |
|
-- |
|
-- |
|
$241.16M |
|
$-241.16M |
|
$4.36M |
|
$-236.80M |
|
$-236.80M |
|
$-236.93M |
|
$-236.93M |
|
$-236.93M |
|
$-236.93M |
|
$-241.16M |
|
$-242.67M |
|
163.39M |
|
163.39M |
|
$-1.45 |
|
$-1.45 |
|
| Balance Sheet Financials | |
$190.54M |
|
$0.04M |
|
$0.51M |
|
$191.05M |
|
$32.45M |
|
$54.53M |
|
$54.73M |
|
$87.18M |
|
$103.87M |
|
$103.87M |
|
$103.87M |
|
174.26M |
|
| Cash Flow Statement Financials | |
$-206.44M |
|
$168.52M |
|
$77.09M |
|
$143.36M |
|
$182.53M |
|
$39.17M |
|
$29.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.87 |
|
-- |
|
-- |
|
0.34 |
|
0.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-206.22M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-228.10% |
-228.10% |
|
-124.02% |
|
-149.57% |
|
$0.60 |
|
$-1.26 |
|
$-1.26 |
|